All In Biotech

Drug Trial Radar · NCT06248008

A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris

An Open, Multicenter, Phase III Extension Clinical Trial to Evaluate the Long-term Safety of ASC40 (Denifanstat) Tablets in Patients With Moderate to Severe Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

Apr 18, 2024

Primary completion

Nov 12, 2025

Study completion Nov 12, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label study designed to determine the long-term safety of ASC40 (Denifanstat) tablets in patients with moderate to severe acne vulgaris enrolled in the ASC40-303 Phase III study. All subjects are eligible for study eligibility screening after enrollment in ASC40-303 Phase III study, and all eligible subjects with moderate to severe acne vulgaris will receive ASC40 (Denifanstat) tablets after signing informed consent. The investigational drug will be administered orally once daily (QD) for up to 40 weeks. There will be a total of 7 visits for screening and follow-up. The tests required by the program included routine blood tests, blood biochemistry, lipid profile, pregnancy test and urine routine, etc.

Conditions

  • Acne

Interventions

  • ASC40Drug

    ASC40 tablets orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and percentage of subjects with treatment emergent adverse events (TEAE)Time frame: From the first dose to 40 weeks of treatment.
  2. Number and percentage of subjects with serious adverse event (SAE).Time frame: From the first dose to 40 weeks of treatment.
  3. Number and percentage of subjects who discontinued due to adverse events.Time frame: From the first dose to 40 weeks of treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.